At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 54 enrolled

Drug / intervention

JNJ-73763989 +4 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04439539

NCT04439539Phase 2Completed

Compare CT.gov

A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog With or Without JNJ-56136379 in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection

Janssen Research & Development, LLC·interventional·Posted Jun 19, 2020·Updated Jun 24, 2025

In Brief

A Phase 2 clinical trial evaluating JNJ-73763989, PegIFN-alpha-2a, and 3 other interventions for Hepatitis B, Chronic. Completed, enrolled 54 participants across 47 sites in 10 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy of a treatment regimen of JNJ-73763989 + pegylated interferon alpha-2a (PegIFN-alpha-2a) + nucleos(t)ide analog (NA).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHepatitis B, Chronic

CountriesCanada, France, Germany, Japan, Russia, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States

Collaborators--

Timeline

Phase 2CompletedFinished

202120222023202420252026

First PostedJun 2020

Enrollment StartSep 2020

Primary CompletionAug 2023

Study CompletionFeb 2024

TodayJul 2026

First PostedJun 19, 2020

Enrollment StartSep 14, 2020

Primary CompletionAug 29, 2023

Study CompletionFeb 13, 2024

TodayJul 2, 2026

Enrollment to primary: 3.0 yearsPosted 6.0 years ago

Interventions

JNJ-73763989drug

JNJ-73763989 injection will be administered subcutaneously.

PegIFN-alpha-2adrug

PegIFN-alpha-2a injection will be administered subcutaneously.

Tenofovir disoproxildrug

Tenofovir disoproxil film-coated tablet will be administered orally.

Tenofovir alafenamidedrug

Tenofovir alafenamide film-coated tablet will be administered orally.

JNJ-56136379drug

JNJ-56136379 will be administered orally.